In collaboration with all regions of the country and the founding company partners, NEXT can now present, as something quite unique, the NEXT Master CDA (Confidential Disclosure Agreement). The document makes it possible to shorten time significantly from the first contact between the company and the clinics to trial start-up.
The CDAs will cover all NEXT (early phase) clinical trials performed on NEXT hospital departments. The following hospitals and companies are part of the CDA collaboration:

Amager and Hvidovre Hospital, Bispebjerg and Frederiksberg Hospital, Herlev and Gentofte Hospital, Naestved Sygehus, Odense University Hospital, Rigshospitalet, Zealand University Hospital, Aalborg University Hospital and Aarhus University Hospital.

AntibioTx, AstraZeneca, Eli Lilly, Larix, LEO Pharma, Novartis, Novo Nordisk, Roche and Statens Serum Institut.

With the NEXT Master CDA, much time will be saved in connection with the start-up of clinical trials since the CDA Appendix 2 is just to be signed by the person who receives the information material about an upcoming company trial. The Appendix 2 of the CDA is not to be presented first at a legal department and then signed by the Hospital Management but can be signed in one day in connection with a feasibility-inquiry about a clinical trial.
We strongly recommend the use of the NEXT Master CDA by the entering of all future CDAs with NEXT hospital departments regarding feasibilities related to NEXT trials.
If your company wants a NEXT CDA please contact Project Director Britta Smedegaard Andersen.